USE OF A DHODH INHIBITOR COMPOUND IN COMBINATION CANCER THERAPY
Provided herein are method of treating lymphomas using an anti-cancer agent and an anti-cancer therapy, wherein the first anti-cancer agent is represented by Formula (I) or a pharmaceutically acceptable salt thereof.
1 . A method for treating lymphoma in a subject, comprising administering to the subject an effective amount of an anti-cancer agent and an effective amount of an anti-cancer therapy, wherein the anti-cancer agent is represented by Formula (I):
or a pharmaceutically acceptable salt thereof; and wherein the anti-cancer therapy comprises a combination of rituximab, cyclophosphamide, doxorubicin or a pharmaceutically acceptable salt thereof, vincristine or a pharmaceutically acceptable salt thereof, and prednisolone.
2 . The method of claim 1 , wherein the lymphoma is a Hodgkin lymphoma.
3 . The method of claim 1 , wherein the lymphoma is a non-Hodgkin lymphoma
4 . The method of claim 1 , wherein the lymphoma is a B-cell lymphoma.
5 . The method of claim 1 , wherein the lymphoma is selected from follicular lymphoma, DLBCL, MCL, Burkitt, and lymphoplasmacytic lymphoma.
6 . The method of claim 1 , wherein the lymphoma is selected from DLBCL, MCL, and Burkitt lymphoma.
7 . The method of claim 1 , wherein the lymphoma is selected from DLBCL and MCL.
8 . The method of claim 1 , wherein the lymphoma is DLBCL.
9 . The method of claim 1 , wherein the lymphoma is a T-cell lymphoma.
10 . The method of claim 1 , wherein the lymphoma is a cutaneous T-cell lymphoma.
11 . The method of claim 1 , wherein the lymphoma is selected from mycosis fungoide, PTCL, AITL, ALCL, EATL, and hepatosplenic gamma/delta T-cell lymphoma.
12 . The method of claim 1 , wherein the anti-cancer agent and the anti-cancer therapy are administered simultaneously in the same or different formulations.
13 . The method of claim 1 , wherein the anti-cancer agent and the anti-cancer therapy are administered sequentially.
14 . The method of claim 1 , wherein the anti-cancer agent is the tris(hydroxymethyl)aminomethane salt of the compound of Formula (I).
15 . The method of claim 1 , wherein the anti-cancer agent is the sodium salt of the compound of Formula (I).
16 . The method of claim 1 , wherein the doxorubicin is doxorubicin hydrochloride.
17 . The method of claim 1 , wherein the vincristine is vincristine sulfate.